<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4154">
  <stage>Registered</stage>
  <submitdate>14/03/2012</submitdate>
  <approvaldate>14/03/2012</approvaldate>
  <nctid>NCT01683695</nctid>
  <trial_identification>
    <studytitle>Safety Study of AMG 557 in Subjects With Lupus Arthritis</studytitle>
    <scientifictitle>A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>20101103</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lupus Arthritis, Systemic Lupus Erythematosus</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AMG 557
Treatment: drugs - Matching Placebo

Active Comparator: AMG 557 - All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141 and Day 155.

Placebo Comparator: AMG 557 Matching Placebo - All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141 and Day 155.


Treatment: drugs: AMG 557
AMG 557 will be administered as subcutaneous injections in the anterior abdomen of the subjects.

Treatment: drugs: Matching Placebo
Placebo will be administered as subcutaneous injections in the anterior abdomen of the subjects.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Treatment-emergent adverse events, vital signs, physical examinations, clinical laboratory tests, ECGs, and the incidence of binding and neutralizing antibodies to AMG 557.</outcome>
      <timepoint>330 days, including a 21-day screening period</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Lupus Arthritis Response Rate - Defined by: 1) achieving at least a 50% decrease in the combined tender and swollen joint count compared to baseline at Day 169; 2) achieving one letter improvement in the Musculoskeletal System BILAG at Day 169 compared to baseline; 3) reduction in and maintenance of prednisone (or its equivalent) dose to = 50% of baseline corticosteroid dose (Day 1 predose) or = 7.5 mg/day, whichever is lower, from Day 85 to Day 169 in subjects not treated with immunosuppressants at baseline, or reduction in and maintenance of prednisone (or its equivalent) dose to = 7.5 mg/day from Day 85 to Day 169 and discontinuation of immunosuppressants by Day 29 in subjects treated with immunosuppressants at baseline</outcome>
      <timepoint>Day 169</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects achieving a) one letter improvement; and b) 'C' or better score in the Musculoskeletal system from BILAG index at Day 169 compared to baseline, by treatment group.</outcome>
      <timepoint>Day 169</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage change in the tender and swollen joint counts at Day 169 relative to baseline.</outcome>
      <timepoint>Day 169</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects achieving reduction in and maintenance = 7.5 mg/day of prednisone (or equivalent) from Day 85- Day 169 and discontinuation of immunosuppressants by Day 29 in subjects treated with immunosuppressants at baseline.</outcome>
      <timepoint>Days 85-169</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects achieving reduction in and maintenance of prednisone (or its</outcome>
      <timepoint>Days 85-169</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physician Global Assessment of Disease Activity (PGADA).</outcome>
      <timepoint>330 days, including a 21-day screening period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subject Global Assessment of Disease Activity (SGADA).</outcome>
      <timepoint>330 days, including a 21-day screening period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum PK profile of AMG 557 after multiple dose administrations.</outcome>
      <timepoint>330 days, including a 21-day screening period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects who discontinued immunosuppressants by Day 29 in subjects</outcome>
      <timepoint>Day 29</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cumulative dose of prednisone (or its equivalent) from Day 85 to Day 169.</outcome>
      <timepoint>Day 85 to Day 169</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of SLE for at least 6 months as defined by the most recent American College
             of Rheumatology criteria

          -  Presence of lupus related inflammatory arthritis with at least four tender and four
             swollen joints; and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) = 6
             at screening;

          -  Other inclusion criteria may apply.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Presence or history of vasculitis, and presence or history of active lupus nephritis
             requiring therapy within the last 3 years

          -  Any disorder (including psychiatric), condition, clinically significant disease,
             disease activity related to SLE

          -  Positive for HIV antibodies, hepatitis B surface antigen or anti-HBc, or hepatitis C
             antibodies

          -  Known residential exposure to an individual with tuberculosis or positive Quantiferon
             test or PPD test at screening

          -  Men and women of reproductive potential, unwilling to practice a highly effective
             method of birth control for the duration of the study

          -  Other exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Research Site - St Leonards</hospital>
    <postcode>2065 - St Leonards</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Odense</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille cedex 01</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Sarawak</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Wilayah Persekutuan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a multicenter, randomized, double-blind, parallel, placebo-controlled, multiple dose
      study that will enroll approximately 40 systemic lupus erythematosus subjects with active
      lupus arthritis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01683695</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>